title: Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
abstract: First line treatment of patients pts with poor-prognosis GCT, using BEP, is unsatisfactory. T-BEP (paclitaxel followed by BEP) demonstrated promising efficacy in the group of pts with intermediate and poor prognosis GCT. We present the results achieved with 1st line T-BEP in pts with poor-prognosis CGT. Twenty-four pts received T-BEP as initial therapy. Three pts (12.5%) had primary mediastinal GCT. Four cycles of T-BEP were given 21 days apart. Paclitaxel 175 mg/m2 was administered on day 1 before administration of BEP. The administration of G-CSF was not scheduled. Surgical resection of all radiographic residua was considered. All pts were assessable for response. Complete or partial response with negative tumor markers was achieved in 13 pts (54.2%; CI 95%: 34.3-74.1%). Median follow-up is 35.6 months. Median survival was not achieved and median time-to-progression is 9.5 months. Myelosuppression was the major toxicity with Gr3-4 granulocytopenia experienced in 52.1% of all courses. There were two treatment-related deaths due to sepsis. Patients treated with 1st line T-BEP didn't achieve higher response rate or time to progression. However, the overall survival observed in our study is surprisingly long. We do not recommend using this regimen without G-CSF support due to substantial toxicity.
authors: National Cancer Institute, Bratislava, Slovakia. jozef.mardiak@nou.sk
authors: J
authors: J
authors: Mardiak
authors: T
authors: T
authors: Sálek
authors: Z
authors: Z
authors: Sycová-Milá
authors: J
authors: J
authors: Obertová
authors: M
authors: M
authors: Recková
authors: M
authors: M
authors: Mego
authors: Z
authors: Z
authors: Hlavatá
authors: K
authors: K
authors: Brozmanová
authors: Z
authors: Z
authors: Risnyovzská
authors: D
authors: D
authors: Svetlovská
authors: I
authors: I
authors: Koza
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D018236:Carcinoma, Embryonal / Q000188:drug therapy / Q000556:secondary; D002822:Choriocarcinoma / Q000188:drug therapy / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D018243:Teratocarcinoma / Q000188:drug therapy / Q000556:secondary; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000556:secondary
chemical_list: D001761:Bleomycin; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin